An international group of researchers is calling for urgent action to curb the use of illicit injectable peptides, a fast growing but poorly understood trend among boys and young men.
Dr Timothy Piatkowski from UQ’s School of Public Health said synthetic peptides, once confined to research and clinical development, were now widely marketed on social media for muscle growth, anti-ageing, injury recovery and cognitive enhancement.
“We are seeing peptides move rapidly from niche biomedical tools into mainstream consumer markets, largely without the scientific evidence or regulatory safeguards typically required for drugs,” Dr Piatkowski said.
“As of May 2026, peptide-related content exceeded 130,000 posts on Instagram and drew more than 230 million views on TikTok and their visibility is growing.
“The way these products are promoted online – often as safe and innovative solutions – creates a real public health blind spot, especially for young people.”
Researchers found peptides have emerged into a “grey zone” spanning medicine, wellness, and illicit drug markets, making them difficult to classify, regulate, and monitor within existing frameworks.
Dr. Kyle T. Ganson, from the University of Toronto, said current regulatory systems were not designed for substances that operate across these markets.
“This creates instability and confusion for clinicians, regulators and consumers, where changing rules may actually drive individuals toward unregulated and potentially riskier sources,” Dr Ganson said.
“The digital environment is a central part of the problem with social media platforms, influencer marketing, and direct-to-consumer supply chains which make the drugs easier to access while normalising their use and minimising perceived risks.”
Dr. Jason M. Nagata, of the University of California, said more research was urgently needed to examine how and why people used peptides, and their potential health consequences.
“Without a stronger evidence base and coordinated oversight, policy responses will continue to lag real-world use,” Dr Nagata said.
“We need a more adaptive, system-wide policy response that extends beyond traditional drug control to address the digital ecosystems and market dynamics driving peptide use.
“This could include stronger oversight of compounding practices, expanded monitoring of adverse effects, enforcement against deceptive online marketing, and greater investment in research and surveillance systems.
“Without these responses, policy will remain reactive and insufficient to protect public health.”
Read the analysis in JAMA.
